



Publications
CYP2C19-Clopidogrel Evidence Overview
Last Updated April 5, 2018

1. Moon JY, Franchi F, Rollini F, Rivas Rios JR, Kureti M, Cavallari LH, Angiolillo DJ. Role of genetic testing in patients undergoing percutaneous coronary intervention. *Expert Rev Clin Pharmacol*. 2018 Feb;11(2):151-164. doi:10.1080/17512433.2017.1353909. Epub 2017 Oct 12. Review. PubMed PMID: 28689434; PubMed Central PMCID: PMC5771818.
2. Cavallari LH, Duarte JD. Clopidogrel pharmacogenetics: from evidence to implementation. *Future Cardiol*. 2016 Sep;12(5):511-4. doi: 10.2217/fca-2016-0045. PubMed PMID: 27539287.
3. Yang Y, Lewis JP, Hulot JS, Scott SA. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. *Expert Opin Drug Metab Toxicol*. 2015;11(10):1599-617. doi: 10.1517/17425255.2015.1068757. Review. PubMed PMID: 26173871; PubMed Central PMCID: PMC4829114.
4. Sabatine MS, Mega JL. Pharmacogenomics of antiplatelet drugs. *Hematology Am Soc Hematol Educ Program*. 2014 Dec 5;2014(1):343-7. doi: 10.1182/asheducation-2014.1.343. Review. PubMed PMID: 25696877.
5. Perry CG, Shuldiner AR. Pharmacogenomics of anti-platelet therapy: how much evidence is enough for clinical implementation? *J Hum Genet*. 2013 Jun;58(6):339-45. doi: 10.1038/jhg.2013.41. Review. PubMed PMID: 23697979; PubMed Central PMCID: PMC3715315.
6. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease--implications for personalized medicine. *Pharmacol Rev*. 2013 May 17;65(3):987-1009. doi: 10.1124/pr.112.007252. Review. PubMed PMID: 23686351; PubMed Central PMCID: PMC3698938.
7. Shahin MH, Johnson JA. Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice? *Curr Opin Cardiol*. 2013 May;28(3):305-14. doi: 10.1097/HCO.0b013e32835f0bbc. Review. PubMed PMID: 23478884; PubMed Central PMCID: PMC3731766.